MTCR Key Statistics, Chart & Performance
The current stock price of MTCR is 0.4949 USD. In the past month the price increased by 8.77%. In the past year, price increased by 6.5%.
MTCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.36 | 390.15B | ||
| AMGN | AMGEN INC | 14.83 | 174.63B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 151.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.86 | 79.76B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 725.41 | 48.88B | ||
| INSM | INSMED INC | N/A | 34.92B | ||
| NTRA | NATERA INC | N/A | 32.83B | ||
| BIIB | BIOGEN INC | 10.65 | 26.16B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.19B | ||
| INCY | INCYTE CORP | 16.11 | 20.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 20.53B |
Related stock screener links
About MTCR
Company Profile
Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The company went IPO on 2020-09-16. The firm is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The firm's program targets the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. The firm's product candidates include MET409 and MET642. The firm is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease characterized by excess liver fat, inflammation and fibrosis. The firm is focused on the farnesoid X receptor (FXR), which is central to modulating gastrointestinal (GI) and liver diseases. The firm is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). Its Inflammatory Bowel Disease (IBD) is a global health issue and is thought to occur due to a maladaptive immune response to gut microbes. UC and Crohn’s disease are the two primary types of IBD.
Company Info
METACRINE INC
4225 Executive Square, Suite 600
San Diego CALIFORNIA 92121 US
CEO: Preston Klassen
Employees: 10
Phone: 18583697800.0
METACRINE INC / MTCR FAQ
Can you describe the business of METACRINE INC?
Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The company went IPO on 2020-09-16. The firm is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The firm's program targets the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. The firm's product candidates include MET409 and MET642. The firm is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease characterized by excess liver fat, inflammation and fibrosis. The firm is focused on the farnesoid X receptor (FXR), which is central to modulating gastrointestinal (GI) and liver diseases. The firm is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). Its Inflammatory Bowel Disease (IBD) is a global health issue and is thought to occur due to a maladaptive immune response to gut microbes. UC and Crohn’s disease are the two primary types of IBD.
What is the stock price of METACRINE INC today?
The current stock price of MTCR is 0.4949 USD. The price decreased by -0.02% in the last trading session.
Does MTCR stock pay dividends?
MTCR does not pay a dividend.
What is the ChartMill technical and fundamental rating of MTCR stock?
MTCR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for MTCR stock?
7 analysts have analysed MTCR and the average price target is 0.51 USD. This implies a price increase of 3.05% is expected in the next year compared to the current price of 0.4949.
When does METACRINE INC (MTCR) report earnings?
METACRINE INC (MTCR) will report earnings on 2023-03-28, after the market close.
MTCR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MTCR. When comparing the yearly performance of all stocks, MTCR is one of the better performing stocks in the market, outperforming 86.79% of all stocks.
MTCR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MTCR. While MTCR seems to be doing ok healthwise, there are quite some concerns on its profitability.
MTCR Financial Highlights
Over the last trailing twelve months MTCR reported a non-GAAP Earnings per Share(EPS) of -0.91. The EPS increased by 69.63% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.34 |
MTCR Forecast & Estimates
7 analysts have analysed MTCR and the average price target is 0.51 USD. This implies a price increase of 3.05% is expected in the next year compared to the current price of 0.4949.